Classification and segmentation deep learning models
Diagnostic TestModels that will be trained on retrospectively acquired data and run on the prospectively acquired data to extract biometric parameters and amniotic volume estimation.
NCT Number: NCT05059093
Routine fetal ultrasound scan during the second trimester of the pregnancy is a low-cost, noninvasive screening modality that has been proven to lower fetal mortality by up to 20%. One of the critical elements of this exam is the measurement of fetal biometric parameters, which are the head circumference (HC), biparietal diameter (BPD), abdominal circumference (AC), and femur length (FL) measured on biometry standard planes. Those standard planes are taken according to quality standards first described by Salomon et al. and used as the guidelines of the International Society of Ultrasound in Obstetrics and Gynecology (ISUOG). The biometric parameters extracted from them are essential to diagnose fetal growth restriction (FGR), the world's first cause of perinatal fetal mortality.
Such measurements and image quality assessment are time-consuming tasks that are prone to inter and intraobserver variability depending on the level of skill of the sonographer or the physician performing the exam.
Amniotic fluid (AF) volume assessment is also an essential step in routine screening scans allowing the diagnosis of oligo or hydramnios, both associated with increased fetal mortality rates.
The AF is measured by two main "semi-quantitative" techniques: Amniotic Fluid Index (AFI) and the single deepest pocket (SDP). The latter is more specific as it lowers the overdiagnosis of oligo-amnios without any impact on mortality or morbidity and is easier to perform for the sonographer (only one measurement versus four in the case of the AFI technique). However, AF assessment remains a time-consuming and poorly reproducible task.
Attempts to automate such biometric measurements and AF volume assessment have been made using Artificial Intelligence (AI) and deep learning (DL) tools. Studies showed excellent results "in silico," reaching up to 98 %, 95%, 93 % dice score coefficients for HC, AC, and FL measurements and 89 % DSC for AFI measurements. However, they were all conducted retrospectively without validation on prospectively acquired images.
Reviews and experts have stressed the need for quality peer-reviewed prospective studies to assess AI tools' performance with real-world data. Their performance is expected to be worse and to reflect better their use in the clinical workflow.
This study aims to develop DL models to automate HC, BPD, AC, and FL measurements and AF volume assessment from retrospectively acquired data and test their performances to those of clinicians and experts on prospective real-world fetal US scans.
Looking for future studies?
Notify Me18 year and older
Female
Observational
Centre Hospitalier Cheikh Khalifa, Casablanca, Morocco
The DL models will be trained, validated, and tested on the retrospectively acquired data first. This data will consist of fetal US images gathered in the participating medical centers after patient-level anonymization. The ground truth for the models will consist of annotations made by radiologists and obstetricians for classification and segmentation purposes. The DL models will be trained to perform the following tasks:
Physicians will be asked to save additional images and video loops additional to their routine screening in the prospective examinations:
The clinicians performing the exam in "real-time"(RT clinicians), the panel of experts, and the DL models will review the prospective examinations.
The SDP measurement extracted by the AF pocket detection and segmentation models will be directly compared to the value measured by the RT clinicians.
Then, the image quality of planes selected by the RT clinicians and the model will be scored by the panel of experts.
The segmentation task will be evaluated in a tripartite fashion: the model, the RT clinicians, and the panel will all segment the same images.
To assess inter-observer agreement, 10% of the images will be randomly selected and reviewed by two independent reviewers from the panel.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Models that will be trained on retrospectively acquired data and run on the prospectively acquired data to extract biometric parameters and amniotic volume estimation.
Time frame: up to 20 weeks
Mean Absolute Error between the model's HC, BPD, AC, FL, and SDP measurements (in mm), the RT clinician's, and the panel's
Time frame: Up to 20 weeks
Overall model's and RT clinician's image quality score assessed by the panel following the ISUOG standards on fetal ultrasound assessment of Biometry and Growth
Time frame: Up to 20 weeks
Overall models' diagnostic accuracy, sensitivity, and specificity at detecting Small-for-Gestational-Age fetuses compared to RT clinicians
Time frame: Up to 20 weeks
Overall models' diagnostic accuracy, sensitivity, and specificity at detecting oligohydramnios and polyhydramnios compared to RT clinicians
Deepecho
Industry
Developing and Testing Deep Learning Models for Fetal Biometry and Amniotic Volume Assessment in Routine Fetal Ultrasound Scans
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05043753
Female Urogenital Diseases and Pregnancy Complications, Large for Gestational Age Infant
Modena, Italy
View Trial DetailsNCT03221933
Small for Gestational Age Infant
Wuhan, Hubei, China
View Trial DetailsNCT04451109
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Diabetes Mellitus
Galveston, Texas, United States
View Trial DetailsNCT00236340
Female Urogenital Diseases and Pregnancy Complications, Polyhydramnios
Tours, Centre-Val de Loire, France
View Trial Details